Tearsheet

Syndax Pharmaceuticals (SNDX)

Market Price (12/28/2025): $21.285 | Market Cap: $1.8 Bil
Sector: Health Care | Industry: Biotechnology

Syndax Pharmaceuticals (SNDX)

Market Price (12/28/2025): $21.285
Market Cap: $1.8 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -25%	Trading close to highs Dist 52W High is -1.8%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -307 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -275%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 597%	Weak multi-year price returns 2Y Excs Rtn is -40%, 3Y Excs Rtn is -91%	Stock price has recently run up significantly 6M Rtn6 month market price return is 136%
2	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.	Meaningful short interest Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.48	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 44%
3			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -279%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -279%
4			Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 60%
5			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21%
6			Significant short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 26%
7			Key risks SNDX key risks include [1] notable safety concerns for its lead drug Revuforj, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -25%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 597%
2	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more.
3	Trading close to highs Dist 52W High is -1.8%
4	Weak multi-year price returns 2Y Excs Rtn is -40%, 3Y Excs Rtn is -91%
5	Meaningful short interest Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.48
6	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -307 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -275%
7	Stock price has recently run up significantly 6M Rtn6 month market price return is 136%
8	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 44%
9	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -279%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -279%
10	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 60%
11	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21%
12	Significant short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 26%
13	Key risks SNDX key risks include [1] notable safety concerns for its lead drug Revuforj, Show more.

Valuation, Metrics & Events

	12/28/25	2024	2023	2022	2021
Share Price CYE	$21.29	$13.22	$21.61	$25.45	$21.89
Market Cap CYE ($ Bil)	1.8	1.1	1.6	1.6	1.2
Total Debt ($ Bil)	0.0	0.3	0.0	0.0	0.0
Total Cash ($ Bil)	0.5	0.6	0.6	0.5	0.4
Enterprise Value ($ Bil)	1.4	1.4	1.6	1.6	1.2
Valuation Ratios
P/S TTM	16.5	47.8	-	-	8.2
P/EBIT TTM	-6.5	-3.6	-7.3	-10.6	42.5
P/E TTM	-5.9	-3.6	-7.3	-10.4	45.7
P/FCF TTM	-5.9	-4.1	-9.5	-11.6	39.3
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9	4.5	7.1
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4	-1.3	-2.6
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3	-2.8
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5	-3.2

	12/28/25	2024	2023
Share Price CYE	$21.29	$13.22	$21.61
Market Cap CYE ($ Bil)	1.8	1.1	1.6
Total Debt ($ Bil)	0.0	0.3	0.0
Total Cash ($ Bil)	0.5	0.6	0.6
Enterprise Value ($ Bil)	1.4	1.4	1.6
Valuation Ratios
P/S TTM	16.5	47.8	-
P/EBIT TTM	-6.5	-3.6	-7.3
P/E TTM	-5.9	-3.6	-7.3
P/FCF TTM	-5.9	-4.1	-9.5
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	SNDX	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.1
Rev Chg Q	267.0%	7.3%
Rev Chg LTM	597.2%	6.1%
Rev Chg 3Y Avg	248.6%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.3
CFO LTM ($ Bil)	-0.3
Net Inc LTM ($ Bil)	-0.3
Op Mgn LTM	-275.1%	18.8%
CFO/Rev LTM	-278.7%	20.4%
Net Inc Mgn	-279.3%	13.1%
VALUATION	VERY HIGH
P/S	16.5	3.3
P/CFO	-5.9	15.8
P/FCF	-5.9	20.7
P/E	-5.9	23.7
STABILITY	VERY GOOD
Debt/Equity	0.00	0.21
Cash/Assets	0.82	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Revuforj Patient Penetration Rate (Relapsed/Refractory KMT2A Acute Leukemia)	0.25	8042025	Link
Niktimvo Patient Retention Rate	0.85	8042025	Link
Total Prescriptions for Revuforj since launch	2200	11032025	Link
Total Patients Treated with Revuforj since launch	750	11042025	Link
Niktimvo Total Infusions since launch	8500	11042025	Link
Niktimvo Total Patients Treated since launch	1100	11042025	Link
Number of Revumenib Abstracts Accepted at ASH 2025	12	11032025	Link
Number of Axatilimab Abstracts Accepted at ASH 2025	11	11032025	Link
AUGMENT-101 Trial Enrollment (Relapsed/Refractory mNPM1 AML)	77	8042025	Link

Upcoming
3/02/2026	Earnings Release	Rev: - EPS: -

SNDX Stock

Return (1M):

null

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Syndax Pharmaceuticals (SNDX) experienced a notable stock movement of 30.4% during the approximate period from August 31, 2025, to December 28, 2025, driven by several key developments:

1. Strong Q2 2025 Financial Performance and Positive Analyst Outlook. Syndax Pharmaceuticals reported better-than-expected financial results for the second quarter of 2025, demonstrating strong sales momentum for its key drugs, Revuforj and Niktimvo. This announcement on August 5, 2025, led to an approximate 21% surge in the stock's premarket trading. Following these results, Citi initiated a 90-day "upside catalyst watch" and raised its price target for SNDX, citing the therapies' market outperformance and potential for expanded use in earlier treatment lines.

2. Accelerated Commercialization of Approved Cancer Therapies. The successful U.S. commercialization and increasing adoption of Revuforj (revumenib), approved by the FDA on November 15, 2024, for relapsed or refractory acute leukemia, contributed significantly to revenue growth. Similarly, Niktimvo (axatilimab), which received FDA approval for chronic graft-versus-host disease in late 2024 and launched in late January 2025, showed strong initial sales. These launches and their subsequent market uptake provided continuous positive momentum for the company.

Stock Movement Drivers

Fundamental Drivers

The 35.8% change in SNDX stock from 9/27/2025 to 12/27/2025 was primarily driven by a 42.7% change in the company's Total Revenues ($ Mil).

	9272025	12272025	Change
Stock Price ($)	15.68	21.30	35.84%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	78.18	111.55	42.68%
P/S Multiple	17.32	16.54	-4.48%
Shares Outstanding (Mil)	86.34	86.62	-0.33%
Cumulative Contribution			35.84%

LTM = Last Twelve Months as of date shown

Market Drivers

9/27/2025 to 12/27/2025

	Return	Correlation
SNDX	35.8%
Market (SPY)	4.3%	8.7%
Sector (XLV)	15.2%	27.6%

Fundamental Drivers

The 135.6% change in SNDX stock from 6/28/2025 to 12/27/2025 was primarily driven by a 155.1% change in the company's Total Revenues ($ Mil).

	6282025	12272025	Change
Stock Price ($)	9.04	21.30	135.62%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	43.72	111.55	155.14%
P/S Multiple	17.82	16.54	-7.17%
Shares Outstanding (Mil)	86.17	86.62	-0.52%
Cumulative Contribution			135.61%

LTM = Last Twelve Months as of date shown

Market Drivers

6/28/2025 to 12/27/2025

	Return	Correlation
SNDX	135.6%
Market (SPY)	12.6%	10.1%
Sector (XLV)	17.0%	23.5%

Fundamental Drivers

The 66.8% change in SNDX stock from 12/27/2024 to 12/27/2025 was primarily driven by a 597.2% change in the company's Total Revenues ($ Mil).

	12272024	12272025	Change
Stock Price ($)	12.77	21.30	66.80%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	16.00	111.55	597.19%
P/S Multiple	68.19	16.54	-75.74%
Shares Outstanding (Mil)	85.43	86.62	-1.39%
Cumulative Contribution			66.76%

LTM = Last Twelve Months as of date shown

Market Drivers

12/27/2024 to 12/27/2025

	Return	Correlation
SNDX	66.8%
Market (SPY)	17.0%	29.6%
Sector (XLV)	13.8%	37.1%

Fundamental Drivers

The -9.3% change in SNDX stock from 12/28/2022 to 12/27/2025 was primarily driven by a -42.8% change in the company's Shares Outstanding (Mil).

	12282022	12272025	Change
Stock Price ($)	23.49	21.30	-9.32%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	126.58	111.55	-11.87%
P/S Multiple	11.26	16.54	46.90%
Shares Outstanding (Mil)	60.67	86.62	-42.77%
Cumulative Contribution			-25.91%

LTM = Last Twelve Months as of date shown

Market Drivers

12/28/2023 to 12/27/2025

	Return	Correlation
SNDX	-1.3%
Market (SPY)	48.0%	30.6%
Sector (XLV)	17.9%	38.3%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
SNDX Return	153%	-2%	16%	-15%	-39%	63%	146%
Peers Return	16%	38%	-12%	21%	26%	16%	150%
S&P 500 Return	16%	27%	-19%	24%	23%	18%	114%
Monthly Win Rates [3]
SNDX Win Rate	58%	50%	58%	42%	33%	58%
Peers Win Rate	52%	65%	42%	68%	57%	52%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
SNDX Max Drawdown	-24%	-40%	-38%	-55%	-42%	-34%
Peers Max Drawdown	-34%	-5%	-26%	-7%	-9%	-23%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)

How Low Can It Go

Unique Key	Event	SNDX	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-60.7%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	154.4%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-36.2%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	56.7%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	104 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-75.8%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	312.8%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	491 days	120 days

Compare to HPQ, HPE, IBM, CSCO, AAPL

In The Past

Syndax Pharmaceuticals's stock fell -60.7% during the 2022 Inflation Shock from a high on 2/1/2023. A -60.7% loss requires a 154.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Syndax Pharmaceuticals (SNDX)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

AI Analysis | Feedback

Here are 1-2 brief analogies to describe Syndax Pharmaceuticals (SNDX):

A biotech company focused on developing new targeted therapies for cancer and immune disorders, much like what Seagen (now part of Pfizer) was in the oncology space.
A specialized biotech with a promising late-stage pipeline, aiming to establish market leadership in specific cancer and immunology niches, similar to how Vertex Pharmaceuticals became a leader in cystic fibrosis treatments.

AI Analysis | Feedback

Axatilimab: A monoclonal antibody targeting the CSF-1R pathway, being developed for chronic graft-versus-host disease (cGVHD) and other fibrotic diseases.
SNDX-5613 (Koelacab™): A highly selective Menin inhibitor, currently in clinical development for the treatment of acute leukemias with specific genetic mutations.

AI Analysis | Feedback

Syndax Pharmaceuticals (SNDX) sells primarily to other companies, specifically major pharmaceutical wholesale distributors. These distributors then supply hospitals, clinics, and other healthcare providers.

According to Syndax Pharmaceuticals' financial filings (e.g., their 2023 10-K), a significant portion of their gross product sales comes from a limited number of wholesale pharmaceutical distributors. In 2023, their three largest wholesale customers accounted for 98% of their gross product sales.

The major customers of Syndax Pharmaceuticals are:

McKesson Corporation (Symbol: MCK)
AmerisourceBergen Corporation (Symbol: ABC)
Cardinal Health, Inc. (Symbol: CAH)

AI Analysis | Feedback

AGC Biologics
Ajinomoto Bio-Pharma Services

AI Analysis | Feedback

Michael A. Metzger, M.B.A. Chief Executive Officer

Michael A. Metzger has served as the Chief Executive Officer of Syndax Pharmaceuticals since February 2022. Prior to this role, he was the President and Chief Operating Officer of the company. Earlier in his career, Mr. Metzger was involved with Regado, a company that underwent a reverse merger.

Keith Alan Goldan, CPA Chief Financial Officer, Treasurer and Chief Accounting Officer

Keith Alan Goldan assumed the role of Chief Financial Officer, Treasurer, and Chief Accounting Officer at Syndax Pharmaceuticals in 2022.

Peter Ordentlich, Ph.D. Co-Founder and Chief Scientific Officer

Peter Ordentlich co-founded Syndax Pharmaceuticals in October 2005 and has served as its Chief Scientific Officer since September 2016. Before co-founding Syndax, he was a research scientist at X-Ceptor Therapeutics, Inc., a drug discovery company that was subsequently acquired by Exelixis, Inc.

Anjali Ganguli, Ph.D. Chief Strategy Officer

Anjali Ganguli was appointed Chief Strategy Officer at Syndax Pharmaceuticals in 2024.

Nicholas Botwood Chief Medical Officer; Head - Research and Development

Nicholas Botwood became the Chief Medical Officer and Head of Research and Development at Syndax Pharmaceuticals in 2025.

AI Analysis | Feedback

The key risks to Syndax Pharmaceuticals (SNDX) largely revolve around the inherent challenges of the biopharmaceutical industry, particularly in drug development, market competition, and financial viability.

Clinical Development and Regulatory Hurdles: Syndax faces significant risks related to the successful completion of clinical trials, obtaining regulatory approvals, and potential delays or failures in these processes. For example, the FDA delayed a decision on one of Syndax's leukemia drugs in 2024. Furthermore, concerns regarding the safety profile of its lead product, Revuforj (revumenib), specifically QTc prolongation and differentiation syndrome, have been noted and have impacted investor sentiment.
Intense Competition and Market Acceptance: The market for acute myeloid leukemia (AML) treatments, where Syndax's Revuforj competes, is highly crowded and competitive. Larger pharmaceutical companies, such as Johnson & Johnson and Kura Oncology, are heavily investing in this area and conducting Phase 3 trials for similar treatments, posing a significant threat to Syndax's market share. Syndax's ability to differentiate its products, achieve sufficient market penetration, and overcome potential commercialization challenges, including scaling production and securing reimbursement, are critical risks, especially given some investor skepticism regarding Revuforj's remission rates.
Path to Profitability and Financial Dependence: Syndax has consistently incurred net losses since its inception and is expected to continue doing so in the near term, primarily due to high research and development costs. The company's financial performance is heavily reliant on the commercial success of its approved products, particularly Revuforj. Any setbacks in the market performance or unexpected safety issues with Revuforj could significantly impede Syndax's progress toward profitability. Additionally, the need for further capital, which may not always be available on favorable terms, remains a financial risk.

AI Analysis | Feedback

Syndax Pharmaceuticals faces an emerging threat from direct competition in the menin inhibitor market for the treatment of MLLr and NPM1-mutant acute leukemias.

Syndax's lead asset, revumenib, a menin inhibitor, is currently in pivotal Phase 2 trials with an NDA submission planned for mid-2024. However, Kura Oncology (symbol: KO) is developing ziftomenib (KO-539), another menin inhibitor, which is also in late-stage clinical development (Phase 2) for relapsed/refractory MLLr acute myeloid leukemia. Both drugs target the same molecular pathway and highly similar patient populations. Clinical trial data released by both companies indicate promising efficacy and safety profiles, setting the stage for direct competition upon potential market entry. The timing of regulatory approvals and the specific differentiating factors in their respective clinical data will significantly influence market share and commercial success for revumenib.

AI Analysis | Feedback

Syndax Pharmaceuticals' main products, Revuforj (revumenib) and Niktimvo (axatilimab), target significant addressable markets.

Revuforj (revumenib)

Revuforj is a menin inhibitor approved for the treatment of relapsed or refractory (R/R) KMT2A-rearranged acute leukemia and, more recently, for R/R mutant nucleophosmin 1 (mNPM1) acute myeloid leukemia (AML).

For its initial approved indications in acute leukemia, the potential market is estimated to be $2 billion.
If Revuforj expands into frontline treatment for AML and ALL patients with KMT2A and NPM1 mutations, the market opportunity could grow to $5 billion.
These market size estimates are generally considered global potential.

Niktimvo (axatilimab)

Niktimvo is a CSF-1 receptor blocking antibody approved for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.

Syndax leadership projects Niktimvo has the potential for $2 billion in annual peak sales for its approved indication.
Niktimvo is also being investigated for idiopathic pulmonary fibrosis (IPF).
This market size estimate is generally considered global potential.

Overall, Syndax Pharmaceuticals estimates a combined market opportunity exceeding $10 billion for both Revuforj and Niktimvo.

AI Analysis | Feedback

Syndax Pharmaceuticals (SNDX) is poised for significant future revenue growth over the next 2-3 years, driven by several key factors:

Expansion of Revuforj (revumenib) into new acute leukemia indications: The recent FDA approval of Revuforj for relapsed/refractory (R/R) NPM1-mutated (mNPM1) acute myeloid leukemia (AML) in October 2025 significantly expands its addressable market beyond KMT2A-rearranged acute leukemia. Additionally, Syndax is actively investigating Revuforj in pivotal trials for frontline settings in both KMT2Ar and mNPM1 acute leukemias, including combinations with standard therapies like venetoclax and azacitidine, which represent a substantial market opportunity.
Continued strong commercial uptake and expansion of Niktimvo (axatilimab) in chronic Graft-versus-Host Disease (GVHD): Niktimvo has demonstrated robust patient uptake and strong commercial performance since its launch for third-line plus chronic GVHD. Future revenue growth is expected from continued market penetration in this indication and potential expansion into earlier lines of therapy for chronic GVHD, with new data on combinations with rituximab in newly diagnosed patients being explored.
Increased duration of therapy for Revuforj (revumenib): The average treatment duration for Revuforj is projected to increase from 4-6 months in 2025 to 6-12 months in 2026. This anticipated increase is largely due to more patients returning to maintenance therapy post-stem cell transplant, contributing to sustained revenue per patient.
Potential expansion of Niktimvo (axatilimab) into Idiopathic Pulmonary Fibrosis (IPF): Beyond its use in chronic GVHD, Syndax is evaluating Niktimvo in a Phase 2 clinical trial (MAXPIRe) for idiopathic pulmonary fibrosis (IPF), with data anticipated in the second half of 2026. This represents a new potential market expansion for the drug.

AI Analysis | Feedback

Share Issuance

Syndax utilizes an at-the-market (ATM) program, specifically the 2021 ATM Program, for issuing shares, which can lead to stockholder dilution.
As of September 30, 2025, Syndax had 87.2 million common shares and prefunded warrants outstanding.
On November 1, 2025, Syndax granted inducement awards for up to 143,500 shares of common stock to four new employees under its 2023 Inducement Plan.

Inbound Investments

In September 2021, Syndax entered into a License and Collaboration Agreement with Incyte for the worldwide development and commercialization of axatilimab (Niktimvo), which included a share purchase agreement with Incyte.
Upon the FDA approval of Niktimvo in August 2024, Syndax earned a revenue milestone of $12.5 million, received in September 2024.
A $350 million royalty financing agreement was secured with Royalty Pharma for Niktimvo, increasing Syndax's pro forma cash position to approximately $750 million as of September 30, 2024.

Capital Expenditures

Syndax's investment in biopharmaceutical product development involves substantial upfront capital expenditures and significant research and development expenses.
For the full year 2025, total research and development plus selling, general, and administrative expenses are projected to be between $380 million and $385 million, excluding approximately $45 million in non-cash stock compensation.
The primary focus of these expenditures is on the commercial launches of Revuforj (launched November 2024) and Niktimvo (launched January 2025), and ongoing pipeline development.

	Best Bets In Health Care Sector
What You Pay
P/E	-5.9	22.1	13.6	32.4	13.7	11.8	78.9	75.0	28.1	11.4	58.0
P/EBIT	-6.5	10.7	10.6	33.2	11.5	8.9	57.4	73.2	27.4	7.7	67.5
What You Get
Rev Chg Q	267.0%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	597.2%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	�	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	�	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Syndax Pharmaceuticals Earnings Notes
2	Is Syndax Pharmaceuticals Stock Built to Withstand a Pullback?	Return
3	Day 6 of Gains Streak for Syndax Pharmaceuticals Stock with 27% Return (vs. 20% YTD) [8/18/2025]	Notification
4	Day 5 of Gains Streak for Syndax Pharmaceuticals Stock with 26% Return (vs. 19% YTD) [8/15/2025]	Notification
5	Syndax Pharmaceuticals (SNDX) Net Income Comparison	Financials
6	Syndax Pharmaceuticals (SNDX) EBITDA Comparison	Financials
7	Syndax Pharmaceuticals (SNDX) Operating Cash Flow Comparison	Financials
8	Syndax Pharmaceuticals (SNDX) Operating Income Comparison	Financials
9	Syndax Pharmaceuticals (SNDX) Debt Comparison	Financials
10	Syndax Pharmaceuticals (SNDX) Tax Expense Comparison	Financials

	Title
0	ARTICLES

Trade Ideas

Select ideas related to SNDX. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.4%	21.4%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.4%	-7.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	18.0%	18.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.9%	3.9%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	12.2%	12.2%	-5.1%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ZETA	Zeta Global	4.6	8.3%	15.1%
SGML	Sigma Lithium	1.6	7.3%	29.2%
USAS	Americas Gold And Silver	1.6	6.6%	557.6%
CPNG	Coupang	44.2	6.4%	10.4%
LION	Lionsgate Studios	2.7	4.6%	-69.9%
BBW	Build-A-Bear Workshop	0.8	4.4%	37.8%
XRAY	Dentsply Sirona	2.3	4.2%	-36.3%
BLMN	Bloomin Brands	0.6	3.8%	-41.2%
FUN	Six Flags Entertainment	1.5	3.8%	-69.1%
SVM	Silvercorp Metals	1.9	3.6%	198.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FLY	Firefly Aerospace	3.3	-13.7%	-61.3%
TMC	TMC The Metals	2.5	-10.5%	508.9%
ORGO	Organogenesis	0.7	-10.1%	64.8%
AAOI	Applied Optoelectronics	2.4	-9.3%	0.8%
BKSY	BlackSky Technology	0.7	-9.0%	79.0%
LUNR	Intuitive Machines	1.8	-8.7%	-16.0%
RCAT	Red Cat	0.8	-8.7%	-35.4%
RGTI	Rigetti Computing	6.7	-8.7%	46.7%
RDW	Redwire	1.0	-8.6%	-56.6%
RKLB	Rocket Lab	36.4	-8.5%	177.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	0.9	71.5%	59.0%
RZLT	Rezolute	0.3	44.3%	-45.5%
DVAX	Dynavax Technologies	1.8	41.5%	20.4%
LUNR	Intuitive Machines	1.8	40.6%	-16.0%
UAMY	United States Antimony	0.7	39.0%	252.5%
FOLD	Amicus Therapeutics	4.4	30.9%	51.3%
ADEA	Adeia	1.9	30.3%	23.0%
HUT	Hut 8	5.2	28.6%	142.3%
AAOI	Applied Optoelectronics	2.4	27.1%	0.8%
SGML	Sigma Lithium	1.6	24.9%	29.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TPL	Texas Pacific Land	6.6	-67.9%	-21.5%
LW	Lamb Weston	5.9	-29.0%	-35.3%
TLRY	Tilray Brands	10.2	-22.2%	-27.8%
TDUP	ThredUp	0.8	-18.2%	348.2%
LAB	Standard BioTools	0.5	-16.9%	-21.1%
OLMA	Olema Pharmaceuticals	2.2	-14.9%	349.9%
EVEX	Eve	1.4	-12.0%	-21.9%
IRON	Disc Medicine	2.8	-11.2%	26.7%
AVO	Mission Produce	0.8	-11.1%	-18.8%
CABO	Cable One	0.7	-10.6%	-67.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TLRY	Tilray Brands	10.2	876.4%	-27.8%
HPP	Hudson Pacific Properties	4.7	452.7%	-51.0%
WVE	WAVE Life Sciences	2.9	139.2%	43.7%
TE	T1 Energy	1.1	106.7%	400.0%
VERA	Vera Therapeutics	3.4	82.1%	26.7%
OMER	Omeros	0.9	66.2%	59.0%
RKLB	Rocket Lab	36.4	65.8%	177.4%
PL	Planet Labs PBC	5.9	65.0%	379.2%
AAOI	Applied Optoelectronics	2.4	63.5%	0.8%
LUNR	Intuitive Machines	1.8	62.4%	-16.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-72.0%	-45.5%
JANX	Janux Therapeutics	0.9	-59.0%	-73.4%
FRMI	Fermi	5.3	-46.0%	-76.6%
LENZ	LENZ Therapeutics	0.5	-43.5%	-41.6%
GOGO	Gogo	0.6	-35.3%	-43.0%
HPK	HighPeak Energy	0.5	-33.9%	-70.4%
PACB	Pacific Biosciences of California	0.5	-32.7%	-3.3%
LDI	loanDepot	0.4	-29.6%	3.9%
ORIC	ORIC Pharmaceuticals	0.6	-29.0%	2.2%
LW	Lamb Weston	5.9	-28.6%	-35.3%

Peer Comparisons for Syndax Pharmaceuticals

Peers to compare with:

Financials

	SNDX	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Syndax P.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Price	21.30	23.26	24.49	305.09	78.16	273.40	51.32
Mkt Cap	1.8	21.9	32.6	284.9	309.2	4,074.4	158.8
Rev LTM	112	55,295	34,296	65,402	57,696	408,625	56,496
Op Inc LTM	-307	3,624	1,644	11,544	12,991	130,214	7,584
FCF LTM	-311	2,800	627	11,854	12,733	96,184	7,327
FCF 3Y Avg	-237	2,978	1,400	11,753	13,879	100,503	7,366
CFO LTM	-311	3,697	2,919	13,483	13,744	108,565	8,590
CFO 3Y Avg	-237	3,672	3,896	13,498	14,736	111,559	8,697

Growth & Margins

	SNDX	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Syndax P.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Rev Chg LTM	597.2%	3.2%	13.8%	4.5%	8.9%	6.0%	7.4%
Rev Chg 3Y Avg	-	-3.9%	6.5%	2.6%	3.7%	1.8%	2.6%
Rev Chg Q	267.0%	4.2%	14.4%	9.1%	7.5%	9.6%	9.4%
QoQ Delta Rev Chg LTM	42.7%	1.1%	3.7%	2.1%	1.8%	2.1%	2.1%
Op Mgn LTM	-275.1%	6.6%	4.8%	17.7%	22.5%	31.9%	12.1%
Op Mgn 3Y Avg	-	7.4%	7.2%	16.4%	24.2%	30.8%	16.4%
QoQ Delta Op Mgn LTM	158.6%	-0.2%	-1.4%	0.6%	0.4%	0.1%	0.2%
CFO/Rev LTM	-278.7%	6.7%	8.5%	20.6%	23.8%	26.6%	14.6%
CFO/Rev 3Y Avg	-	6.8%	12.7%	21.4%	26.1%	28.4%	21.4%
FCF/Rev LTM	-278.7%	5.1%	1.8%	18.1%	22.1%	23.5%	11.6%
FCF/Rev 3Y Avg	-	5.5%	4.6%	18.6%	24.6%	25.6%	18.6%

Valuation

	SNDX	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Syndax P.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Cap	1.8	21.9	32.6	284.9	309.2	4,074.4	158.8
P/S	16.5	0.4	1.0	4.4	5.4	10.0	4.9
P/EBIT	-6.5	6.8	19.9	25.1	22.5	31.3	21.2
P/E	-5.9	8.6	572.7	36.0	29.9	41.0	33.0
P/CFO	-5.9	5.9	11.2	21.1	22.5	37.5	16.2
Total Yield	-16.9%	14.1%	2.3%	5.0%	5.4%	2.8%	3.9%
Dividend Yield	0.0%	2.5%	2.1%	2.2%	2.1%	0.4%	2.1%
FCF Yield 3Y Avg	-17.7%	10.6%	5.5%	6.4%	6.0%	3.1%	5.7%
D/E	0.0	0.5	0.7	0.2	0.1	0.0	0.2
Net D/E	-0.2	0.3	0.6	0.2	0.0	0.0	0.1

Returns

	SNDX	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Syndax P.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
1M Rtn	7.2%	-1.8%	14.4%	0.6%	2.7%	-1.5%	1.7%
3M Rtn	35.8%	-11.9%	2.7%	7.9%	17.0%	7.1%	7.5%
6M Rtn	135.6%	-4.0%	34.5%	6.6%	15.2%	36.3%	24.9%
12M Rtn	66.8%	-27.0%	16.2%	40.5%	34.5%	7.5%	25.3%
3Y Rtn	-9.3%	-1.9%	71.1%	143.1%	81.3%	120.2%	76.2%
1M Excs Rtn	7.1%	-5.6%	12.9%	-2.2%	-0.0%	-3.7%	-1.1%
3M Excs Rtn	31.5%	-16.2%	-1.7%	3.6%	12.7%	2.8%	3.2%
6M Excs Rtn	123.4%	-16.3%	22.3%	-5.7%	3.0%	24.0%	12.6%
12M Excs Rtn	44.0%	-42.9%	-0.7%	25.0%	19.9%	-8.4%	9.6%
3Y Excs Rtn	-91.5%	-83.5%	-11.2%	59.6%	-1.2%	28.4%	-6.2%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for More

					Post-Approval Fwd Returns
FDA App #	Brand Name	Generic Name	Dosage Form	FDA Approval	3M Rtn	6M Rtn	1Y Rtn	2Y Rtn	Total Rtn
NDA218944	REVUFORJ	revumenib citrate	tablet	11152024	-5.7%	-42.8%	5.0%	34.6%	34.6%

	Post-Approval Fwd Returns
NDA218944	REVUFORJ	revumenib citrate	tablet	11152024	-5.7%	-42.8%	5.0%	34.6%	34.6%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/3/2025	3/3/2025	2/27/2024	2/28/2023	3/1/2022	3/12/2021	3/5/2020
Key Financials
Total Revenue	112	24	0	0	140	2	2
EBITDA	-283	-314	-209	-146	27	-71	-56
Operating Income	-307	-340	-230	-152	26	-71	-58
Net Income	-312	-319	-209	-149	25	-73	-56
EPS	-3.61	-3.72	-2.98	-2.46	0.48	-1.87	-1.84
Growth Rates
Total Revenue Growth	597.2%	∞%	-	-100.0%	9109.6%	0.0%	0.0%
EBITDA Growth	4.8%	-50.1%	-43.1%	-644.0%	138.0%	-26.4%	24.3%
Operating Income Growth	4.5%	-47.7%	-51.5%	-678.8%	136.7%	-24.1%	24.2%
Net Income Growth	-4.9%	-52.3%	-40.2%	-699.1%	134.1%	-30.5%	24.2%
Margins
EBITDA Margin	-253.3%	-1325.3%	-	-	19.2%	-4661.3%	-3688.5%
Operating Income Margin	-275.1%	-1434.4%	-	-	18.8%	-4708.2%	-3792.9%
Net Income Margin	-279.3%	-1346.1%	-	-	17.8%	-4822.5%	-3694.6%
Cash & Debt
Total Cash	454	583	578	484	447	293	60
Total Debt	2	346	2	1	21	21	1
Net Debt / (Cash)	-453	-237	-576	-483	-426	-273	-59
Cash Flows
Net Cash from Operations	-311	-275	-161	-134	29	-71	-51
Free Cash from Operations	-311	-275	-161	-134	29	-71	-51
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/3/2025	8/4/2025	5/5/2025	3/3/2025	11/5/2024	8/1/2024	5/8/2024	2/27/2024	11/2/2023	8/3/2023	5/8/2023	2/28/2023
Key Financials Quarterly
Total Revenue	46	38	20	8	12	4	0	0	0	0	0	0
Ebitda	-52	-64	-77	-89	-84	-68	-72	-72	-51	-45	-41	-39
Operating Income	-57	-69	-84	-96	-90	-74	-80	-78	-56	-50	-46	-42
Net Income	-61	-72	-85	-94	-84	-68	-72	-72	-51	-45	-41	-39
EPS	-0.70	-0.83	-0.98	-1.10	-0.98	-0.80	-0.85	-1.00	-0.73	-0.64	-0.59	-0.62
Key Financials TTM
Total Revenue TTM	112	78	44	24	16	4	0	0	0	0	0	0
Ebitda TTM	-283	-314	-318	-314	-297	-264	-240	-209	-176	-158	-151	-146
Operating Income TTM	-307	-339	-344	-340	-321	-288	-263	-230	-194	-173	-161	-152
Net Income TTM	-312	-335	-331	-319	-297	-264	-241	-209	-176	-160	-153	-149
Growth Rates Quarterly
Total Revenue Growth	267.0%	984.5%	-	-	-	-	-	-	-	-	-	-100.0%
EBITDA Growth	37.7%	5.9%	-6.2%	-23.4%	-64.7%	-52.6%	-76.1%	-85.0%	-51.8%	-20.9%	-12.5%	-140.7%
Operating Income Growth	35.9%	6.6%	-5.3%	-23.7%	-59.0%	-49.4%	-72.8%	-85.3%	-60.4%	-31.7%	-24.8%	-143.9%
Net Income Growth	27.8%	-5.6%	-17.2%	-29.9%	-64.5%	-52.6%	-76.0%	-84.9%	-44.5%	-18.7%	-10.6%	-140.7%
Margins Quarterly
EBITDA Margin	-114.3%	-168.6%	-383.2%	-1163.6%	-672.8%	-1943.3%	-	-	-	-	-	-
Operating Income Margin	-125.2%	-182.7%	-417.9%	-1254.8%	-716.6%	-2120.5%	-	-	-	-	-	-
Net Income Margin	-132.4%	-189.3%	-423.3%	-1226.2%	-673.0%	-1944.7%	-	-	-	-	-	-
Cash & Debt
Total Cash	454	469	516	583	406	432	443	578	374	406	438	484
Total Debt	2	2	2	346	1	1	1	2	2	2	1	1
Net Debt / (Cash)	-453	-467	-514	-237	-406	-431	-442	-576	-372	-404	-437	-483
Cash Flows Quarterly
FCF from Operations	-71	-88	-95	-57	-62	-72	-84	-41	-45	-35	-39	-23
Cash Flows TTM
FCF from Operations TTM	-311	-303	-287	-275	-259	-241	-205	-161	-142	-126	-131	-134
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-20.9%	-26.0%	-33.3%	-30.3%	-32.9%	-28.4%	-31.0%	-35.4%	-27.6%	-25.6%	-25.1%	-24.8%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-27.9%	-31.7%	-34.2%	-26.7%	-29.5%	-27.5%	-25.7%	-26.1%	-23.8%	-22.3%	-22.0%	-22.4%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Syndax Pharmaceuticals				2	2
Total				2	2

Assets by Segment

$ Mil	2024	2023	2022	2021	2020
Syndax Pharmaceuticals	613	497	450
Total	613	497	450

Price Behavior

Price Behavior

Market Price	$21.30
Market Cap ($ Bil)	1.8
First Trading Date	03/03/2016
Distance from 52W High	-1.8%
	50 Days	200 Days
DMA Price	$17.60	$13.75
DMA Trend	up	up
Distance from DMA	21.0%	54.9%
	3M	1YR
Volatility	62.8%	68.8%
Downside Capture	-2.47	82.93
Upside Capture	145.52	120.95
Correlation (SPY)	9.8%	29.7%

SNDX Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.86	0.13	0.28	0.57	1.03	1.12
Up Beta	4.48	1.61	2.42	1.20	0.95	1.11
Down Beta	-1.25	-0.65	-1.16	-0.83	1.21	1.17
Up Capture	386%	100%	78%	192%	106%	88%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	11	21	31	67	127	367
Down Capture	-181%	-83%	-15%	22%	100%	105%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	9	21	32	58	121	381

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of SNDX With Other Asset Classes (Last 1Y)
	SNDX	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	62.8%	15.1%	17.8%	72.1%	8.6%	4.4%	-8.2%
Annualized Volatility	68.3%	17.2%	19.4%	19.3%	15.2%	17.0%	35.0%
Sharpe Ratio	0.99	0.65	0.72	2.70	0.34	0.09	-0.08
Correlation With Other Assets		37.1%	29.5%	6.1%	8.9%	32.6%	14.1%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of SNDX With Other Asset Classes (Last 5Y)
	SNDX	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-3.5%	8.4%	14.7%	18.7%	11.5%	4.6%	30.8%
Annualized Volatility	58.0%	14.5%	17.1%	15.5%	18.7%	18.9%	48.6%
Sharpe Ratio	0.18	0.40	0.70	0.97	0.50	0.16	0.57
Correlation With Other Assets		31.3%	30.6%	6.0%	4.7%	27.8%	14.2%

Based On 10-Year Data

		Comparison of SNDX With Other Asset Classes (Last 10Y)
	SNDX	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	6.0%	9.9%	14.8%	15.3%	7.0%	5.3%	69.2%
Annualized Volatility	72.5%	16.6%	18.0%	14.7%	17.6%	20.8%	55.8%
Sharpe Ratio	0.39	0.49	0.71	0.86	0.32	0.22	0.90
Correlation With Other Assets		26.5%	27.6%	4.7%	9.2%	21.6%	10.0%

Short Interest

Short Interest: As Of Date	12152025
Short Interest: Shares Quantity	22,826,193
Short Interest: % Change Since 11302025	-9.5%
Average Daily Volume	1,829,420
Days-to-Cover Short Interest	12.48
Basic Shares Quantity	86,620,992
Short % of Basic Shares	26.4%

Returns Analyses

	Title
0	Is Syndax Pharmaceuticals Stock Built to Withstand a Pullback?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/3/2025	11.6%	14.2%	43.5%
8/4/2025	21.1%	20.5%	55.4%
3/3/2025	-1.0%	-14.2%	-21.5%
11/5/2024	8.4%	-17.7%	-14.7%
8/1/2024	-4.4%	-9.1%	-6.6%
5/8/2024	-3.5%	-6.6%	-16.3%
2/27/2024	-2.2%	-6.0%	-5.5%
11/2/2023	0.1%	-8.8%	13.0%
...
SUMMARY STATS
# Positive	13	10	10
# Negative	7	10	10
Median Positive	5.2%	6.9%	17.9%
Median Negative	-2.2%	-7.7%	-6.0%
Max Positive	21.7%	28.0%	55.4%
Max Negative	-4.4%	-17.7%	-21.5%

	Forward Returns
11/3/2025	11.6%	14.2%	43.5%
8/4/2025	21.1%	20.5%	55.4%
3/3/2025	-1.0%	-14.2%	-21.5%
11/5/2024	8.4%	-17.7%	-14.7%
8/1/2024	-4.4%	-9.1%	-6.6%
5/8/2024	-3.5%	-6.6%	-16.3%
2/27/2024	-2.2%	-6.0%	-5.5%
11/2/2023	0.1%	-8.8%	13.0%
8/3/2023	-2.9%	-9.7%	-3.9%
2/28/2023	-1.9%	-4.4%	-15.0%
11/3/2022	0.4%	5.2%	13.9%
8/8/2022	-1.2%	1.9%	-4.0%
3/1/2022	0.3%	5.9%	7.4%
11/15/2021	2.3%	-0.4%	6.0%
8/9/2021	5.2%	8.0%	21.9%
3/8/2021	1.6%	1.1%	-4.2%
11/2/2020	10.9%	16.5%	33.4%
8/6/2020	5.6%	5.2%	-0.1%
3/3/2020	21.7%	28.0%	2.8%
11/7/2019	0.1%	-3.0%	24.9%
SUMMARY STATS
# Positive	13	10	10
# Negative	7	10	10
Median Positive	5.2%	6.9%	17.9%
Median Negative	-2.2%	-7.7%	-6.0%
Max Positive	21.7%	28.0%	55.4%
Max Negative	-4.4%	-17.7%	-21.5%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11032025	10-Q 9/30/2025
6302025	8042025	10-Q 6/30/2025
3312025	5052025	10-Q 3/31/2025
12312024	3032025	10-K 12/31/2024
9302024	11052024	10-Q 9/30/2024
6302024	8012024	10-Q 6/30/2024
3312024	5082024	10-Q 3/31/2024
12312023	2272024	10-K 12/31/2023
9302023	11022023	10-Q 9/30/2023
6302023	8032023	10-Q 6/30/2023
3312023	5082023	10-Q 3/31/2023
12312022	2282023	10-K 12/31/2022
9302022	11032022	10-Q 9/30/2022
6302022	8082022	10-Q 6/30/2022
3312022	5092022	10-Q 3/31/2022
12312021	3012022	10-K 12/31/2021

Insider Activity

Expand for Morenull

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Syndax Pharmaceuticals (SNDX)

Market Price (12/28/2025): $21.285 | Market Cap: $1.8 BilSector: Health Care | Industry: Biotechnology

Syndax Pharmaceuticals (SNDX)

Market Price (12/28/2025): $21.285Market Cap: $1.8 BilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

SNDX Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Syndax Pharmaceuticals (SNDX)

Interactive Breakdown

Better Bets than Syndax Pharmaceuticals (SNDX)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Syndax Pharmaceuticals

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/28/2025): $21.285 | Market Cap: $1.8 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (12/28/2025): $21.285
Market Cap: $1.8 Bil
Sector: Health Care
Industry: Biotechnology